Short answer
Schrodinger, Inc. (SDGR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 FY2026 results released August 5, 2026, covering quarter ended June 30, 2026.
Schrodinger, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 FY2026 results released August 5, 2026, covering quarter ended June 30, 2026
- Full financial results furnished in Exhibit 99.1, requiring review for revenue, profitability, and guidance
- Disclosure not deemed “filed” under Exchange Act Section 18, limiting associated liability protections
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $58.9M, up 8%, led by drug discovery revenue $23.0M versus $13.9M
- ACV $29.6M, up 27%, while software revenue fell 10% to $32.5M amid the hosted-licensing transition
- Net income $6.0M versus $43.2M loss, driven largely by $45.9M fair-value gains on equity investments
- Cash, restricted cash and marketable securities $418.8M, but operating cash flow was negative $48.9M in the first half
- 2026 ACV outlook $218M-$228M, with drug discovery revenue guidance raised to $65M-$75M after the $10M Ajax milestone
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Schrodinger, Inc. 8-K filings
Get the next SDGR 8-K as it lands
Follow SDGR for push alerts, or ask the research agent what this filing means.